Kubitza, Dagmar
92  results:
Search for persons X
?
3

Effects of Tablet Formulation, Food, or Gastric pH on the B..:

Kanefendt, Friederike ; Brase, Christine ; Unger, Sigrun.
Clinical Pharmacology in Drug Development.  12 (2022)  2 - p. 219-230 , 2022
 
?
4

Dosing Regimen Prediction and Confirmation With Rivaroxaban..:

Zhu, Peijuan ; Willmann, Stefan ; Zhou, Wangda...
The Journal of Clinical Pharmacology.  62 (2022)  2 - p. 220-231 , 2022
 
?
5

Pharmacokinetics, pharmacodynamics and safety of BAY 243333..:

Kubitza, Dagmar ; Heckmann, Michael ; Distler, Jana...
British Journal of Clinical Pharmacology.  88 (2022)  7 - p. 3447-3462 , 2022
 
?
6

Model‐informed bridging of rivaroxaban doses for thrombopro..:

Willmann, Stefan ; Ince, Ibrahim ; Ahsman, Maurice...
CPT: Pharmacometrics & Systems Pharmacology.  11 (2022)  8 - p. 1111-1121 , 2022
 
?
7

Population pharmacokinetic analysis of rivaroxaban in child..:

Willmann, Stefan ; Coboeken, Katrin ; Zhang, Yang...
CPT: Pharmacometrics & Systems Pharmacology.  10 (2021)  10 - p. 1195-1207 , 2021
 
?
9

Rivaroxaban for treatment of pediatric venous thromboemboli..:

Young, Guy ; Lensing, Anthonie W. A. ; Monagle, Paul...
Journal of Thrombosis and Haemostasis.  18 (2020)  7 - p. 1672-1685 , 2020
 
?
11

Enhancing the Quality of Rivaroxaban Exposure Estimates Usi..:

Solms, Alexander ; Frede, Matthias ; Berkowitz, Scott D....
CPT: Pharmacometrics & Systems Pharmacology.  8 (2019)  11 - p. 805-814 , 2019
 
?
13

Integrated Population Pharmacokinetic Analysis of Rivaroxab..:

Willmann, Stefan ; Zhang, Liping ; Frede, Matthias...
CPT: Pharmacometrics & Systems Pharmacology.  7 (2018)  5 - p. 309-320 , 2018
 
1-15